Evidence map›Paper›PMID 41348279›Full record

Observational studyHormones (Athens, Greece)2026

A tertiary-center experience of patients with simultaneous medullary and papillary thyroid carcinomas.

Georgios Boutzios, Zoe Garoufalia, Myrto D Keramida, Dimitra Karaviti, Stavroula A Paschou, Eleftherios Spartalis, Gerasimos Tsourouflis

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Georgios BoutziosEndocrine Unit, Department of Pathophysiology, National and Kapodistrian University of Athens, Mikras Asias 75, Goudi-Attica, 11527, Athens, PC, Greece. gboutzios@med.uoa.gr.ORCID http://orcid.org/0000-0001-6650-3303
Zoe GaroufaliaSecond Department of Propaedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Myrto D KeramidaSecond Department of Propaedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Dimitra KaravitiEndocrine Unit and Diabetes Centre, Department of Clinical Therapeutics, School of Medicine, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0009-0007-2220-1152
Stavroula A PaschouEndocrine Unit and Diabetes Centre, Department of Clinical Therapeutics, School of Medicine, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0002-0651-1376
Eleftherios SpartalisSecond Department of Propaedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Gerasimos TsourouflisSecond Department of Propaedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePapillary thyroid carcinoma (PTC) and medullary thyroid carcinoma (MTC) are thyroid carcinomas of different embryological origin. Over the past few decades, several cases have been reported in which PTC and MTC coexist in the same lymph node but separated by normal tissue, this being termed mixed medullary/follicular thyroid carcinoma (MMFTC). Our study aimed to investigate the prevalence of PTC in a cohort of MTC patients in an attempt to define (a) the clinical phenotype of patients with MTC/PTC and (b) any potent association with age, carcinoembryonic antigen (CEA), calcitonin levels, gender or number of operations. MATERIALS AND

methodsThis is a single-center retrospective observational study of an endocrinology outpatient clinic at a tertiary general university hospital. All patients diagnosed with MTC/PTC between November 2017 and March 2021 were recruited. Those with positive RET were excluded. Statistical analysis was performed using SPSS software (SPSS 25. Inc. Chicago, IL).

resultsA total of 30 patients with MTC/PTC, either as separate tumors or as collision tumors combining MTC and PTC, were included in our study. The mean age was 58.43 ± 12.31 years. Slightly over half of the patients were males (53.3%). Univariate analysis showed no association between MTC/PTC, either as separate tumors or as collision tumors, coexistence and age, calcitonin levels, CEA, gender, number of metastases, or number of operations. Multivariate analysis confirmed no significant associations, although the small sample size limited its scope.

conclusionIn our small case series, no association was demonstrated between simultaneous MTC/PTC and age, CEA, calcitonin levels, gender, or number of operations. This entity likely represents a primary tumor with an incidental pathologic finding of a second malignancy.

Indexed as

Carcinoma, NeuroendocrineThyroid Cancer, PapillaryThyroid NeoplasmsAdultAgedCarcinoembryonic AntigenFemaleHumansMaleMiddle AgedRetrospective StudiesTertiary Care CentersCarcinoembryonic AntigenMedullary thyroid carcinomaPapillary thyroid carcinoma

Identifiers

PMID41348279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.